Shots:

• Baxter’s ready to use Eptifibatide is approved and launched for patients with acute coronary syndrome (ACS) & percutaneous coronary intervention (PCI)
• The FDA approval strengthens Baxter's premix portfolio- enhance patient’s safety by avoiding dosing error and reduces the burden on hospital pharmacist
• Eptifibatide (75mg/100ml) is a platelet aggregation inhibitor- based on Baxter’s galaxy container technology that enhances the shelf life of premixed therapies- currently available in the US

Ref: Baxter| Image: The Baxter Bulletin